Verrica Pharmaceuticals (NASDAQ:VRCA – Get Free Report) is one of 896 publicly-traded companies in the “Pharmaceuticals” industry, but how does it weigh in compared to its peers? We will compare Verrica Pharmaceuticals to related companies based on the strength of its institutional ownership, dividends, risk, earnings, analyst recommendations, profitability and valuation.
Risk & Volatility
Verrica Pharmaceuticals has a beta of 1.69, suggesting that its share price is 69% more volatile than the S&P 500. Comparatively, Verrica Pharmaceuticals’ peers have a beta of -3.76, suggesting that their average share price is 476% less volatile than the S&P 500.
Analyst Recommendations
This is a breakdown of current recommendations and price targets for Verrica Pharmaceuticals and its peers, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Verrica Pharmaceuticals | 1 | 1 | 3 | 0 | 2.40 |
| Verrica Pharmaceuticals Competitors | 7774 | 13861 | 25736 | 1032 | 2.41 |
Verrica Pharmaceuticals currently has a consensus price target of $12.67, suggesting a potential upside of 267.15%. As a group, “Pharmaceuticals” companies have a potential upside of 23.98%. Given Verrica Pharmaceuticals’ higher possible upside, equities research analysts clearly believe Verrica Pharmaceuticals is more favorable than its peers.
Valuation & Earnings
This table compares Verrica Pharmaceuticals and its peers top-line revenue, earnings per share and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Verrica Pharmaceuticals | $35.58 million | -$17.89 million | -2.07 |
| Verrica Pharmaceuticals Competitors | $3.56 billion | $3.19 billion | 548.12 |
Verrica Pharmaceuticals’ peers have higher revenue and earnings than Verrica Pharmaceuticals. Verrica Pharmaceuticals is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
Profitability
This table compares Verrica Pharmaceuticals and its peers’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Verrica Pharmaceuticals | -102.84% | -407.11% | -70.17% |
| Verrica Pharmaceuticals Competitors | -2,381.20% | -218.66% | -15.76% |
Institutional and Insider Ownership
42.5% of Verrica Pharmaceuticals shares are owned by institutional investors. Comparatively, 32.5% of shares of all “Pharmaceuticals” companies are owned by institutional investors. 52.9% of Verrica Pharmaceuticals shares are owned by company insiders. Comparatively, 14.1% of shares of all “Pharmaceuticals” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Summary
Verrica Pharmaceuticals peers beat Verrica Pharmaceuticals on 7 of the 13 factors compared.
About Verrica Pharmaceuticals
Verrica Pharmaceuticals Inc., a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts. The company also develops VP-315, an oncolytic peptide-based injectable therapy, which is in phase II clinical trial for the treatment of dermatology oncologic conditions which includes basal cell carcinoma; and VP-103, a cantharidin-based product candidate for the treatment of plantar warts and is in phase II clinical trial. In addition, it offers YCANTH for the treatment of molluscum contagiosum. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for dermatological oncology indications, such as non-metastatic melanoma and non-metastatic merkel cell carcinoma. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.
Receive News & Ratings for Verrica Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verrica Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
